Cyclopharm

Cyclomedica expands Technegas applications through ongoing research.

Come and meet our team at Exhibitor #17, where we’ll be showcasing Technegas and offering live demonstrations of the technology.

The Cyclomedica team looks forward to connecting with nuclear medicine professionals at the Midlands Technical College Airport Campus in West Columbia, South Carolina, to share insights and discuss the latest developments in functional lung imaging with Technegas.

A global nuclear medicine and molecular imaging provider

Cyclomedica develops nuclear medicine solutions, including Technegas, for lung ventilation imaging since 1986.

Cyclomedica aims to improve respiratory patient outcomes through early intervention and better care management using its technology.

From outstanding healthcare solutions to market excellence: Cyclopharm’s blueprint for growth.

Cyclomedica and its partners support customers in 65 countries.

Cyclomedica innovates in functional lung imaging to improve outcomes for patients with lung conditions.

Cyclopharm and Western University are collaborating on the **PAXT1 clinical trial** to test whether **Technegas®** can detect hidden lung airflow issues in patients with **mild asthma**. The study involves **40 participants aged 17–35** and examines cases where symptoms appear controlled but underlying problems may persist. Researchers aim to assess the diagnostic potential of the technology in identifying subtle respiratory dysfunction.

Nov 2025Cyclomedica - A global nuclear medicine and molecular imaging providerNews article

Cyclopharm Limited extends the US patent protection for **Technegas**, its carbon-32-labeled medical gas used in cancer treatments. The patent extension covers the full maximum period allowed under US law, reinforcing its intellectual property position for the product. Technegas is currently in late-stage development for clinical applications.

Jun 2025listcorp.comNews article

Cyclopharm Limited releases its 2024 first-half trading performance update, detailing financial results and operational progress. The company highlights expansion efforts in the U.S. market as part of its growth strategy. Key developments include strategic moves to strengthen its pipeline of pharmaceutical products.

Aug 2024listcorp.comNews article

The U.S. FDA approves **Technegas®**, a medical gas generator produced by **Cyclopharm**. The company will begin immediate commercial distribution, starting with 200 generators, with the first shipments arriving in the U.S. by early November. Cyclopharm will utilize its global sales network—already operational in 64 countries—to drive adoption, leveraging its existing expertise in marketing and distribution.

Oct 2023Cyclomedica - A global nuclear medicine and molecular imaging providerNews article